FDA Granted a Single 79-Year-Old Patient Compassionate Access to Lilly's Experimental Obesity Drug. The White House Won't Say If That Patient Is Trump.
A solo expanded-access request for Eli Lilly's still-unapproved obesity drug retatrutide was filed in April on behalf of a 79-year-old with refractory obesity, sleep apnea, and pulmonary hypertension — conditions not listed in Trump's last public medical memo. The White House has not confirmed or denied that the patient is the president. The FDA notice itself is so sparse that the program's own founder says something is wrong with how it was listed.